Entry into a Material Definitive Agreement ​ On August 28, 2026, NextCure, Inc. (the "Company") and ARE-8000/9000/10000 Virginia Manor, LLC entered into a Ninth Amendment to the parties’ lease agreement dated January 30, 2019 (the "Amendment") with respect to the Company's remaining approximately 29,864 rentable square feet of leased laboratory and office space located at 8000 Virginia Manor Road, Beltsville, Maryland. Pursuant to the Amendment, the Company vacated and surrendered the premise…

Results of Operations and Financial Condition ​ On August 6, 2026, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. ​ The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or o…

Entry into a Material Definitive Agreement Merger Agreement On July 14, 2026, NextCure, Inc., a Delaware corporation (“ NextCure ” or “ Parent ”), Neptune Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of NextCure (“ First Merger Sub ”), Neptune Second Merger Sub, LLC, a Delaware limited liability company and a wholly owned subsidiary of NextCure (“ Second Merger Sub ” and, together with First Merger Sub, the “ Merger Subs ”), and Avere Therapeutics, Inc., a Delaware c…

The filing appears to be about compensatory arrangements rather than a management change.

Other Events SIM0505 Clinical Program Update On July 14, 2026, NextCure announced that it no longer intends to expand the clinical site footprint for SIM0505 into Europe and Canada. SIM0505 is a novel antibody drug conjugate (“ ADC ”) directed to cadherin-6 (or CDH6) and featuring a proprietary topoisomerase 1 inhibitor payload, which NextCure licensed from Simcere Zaiming Pharmaceutical Co., Ltd. (“ Simcere Zaiming ”). NextCure holds exclusive global rights to develop, manufacture and commer…

Costs Associated with Exit or Disposal Activities The Board of Directors of NextCure approved a restructuring and workforce reduction plan (the “ Plan ”) intended to better align NextCure’s workforce and operations with the anticipated needs of its business pending the closing of the Merger. The Plan is expected to begin in July 2026 and result in a reduction in force affecting a substantial majority of NextCure’s workforce during the quarter ending September 30, 2026, in conjunction with the…

Changes in Control of Registrant To the extent required by this Item, the information included in

The filing is about the approval of an amendment and restatement of a compensation plan, not a management change.

Results of Operations and Financial Condition ​ On May 7, 2026, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. ​ The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth…

Results of Operations and Financial Condition ​ On March 5, 2026, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December31, 2025. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. ​ The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the ”Exchange Act”), or ot…

are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to statements related to our cash runway and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our therapies. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statem…

Results of Operations and Financial Condition ​ On January 23, 2026, NextCure, Inc. (the “Company”) issued a press release announcing preliminary results that as of December 31, 2025, it had approximately $41.8 million in cash, cash equivalents and marketable securities. The Company expects current financial resources to be sufficient to fund planned operating expenses and capital expenditures into the first half of 2027. ​ Because the Company’s consolidated financial statements for the year…

Other Events. On December 19, 2025, NextCure, Inc. (the “Company”) entered into an at the market offering agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”), pursuant to which the Company may sell, from time to time, up to an aggregate sales price of $14,500,000 of its common stock, $0.001 par value per share (the “Common Stock”), through the Agent. Actual sales will depend on a variety of factors to be determined by the Company from time to time, including, among o…

Entry into a Material Definitive Agreement Securities Purchase Agreement On November 12, 2025, NextCure, Inc. (“NextCure” or the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”) for a private placement (the “Offering”) of an aggregate of (i) 708,428 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at…

Unregistered Sales of Equity Securities ​ To the extent required by Form 8-K, the disclosures in

Results of Operations and Financial Condition On November 5, 2025, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. The company is furnishing a copy of the press release, which is attached hereto as exhibit 99.1. ​ The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…

Chief Scientific Officer — Solomon Langermann, Ph.D.: Dr. Solomon Langermann resigned from his position as Chief Scientific Officer.

Results of Operations and Financial Condition On August 7, 2025, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. ​ The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth…

Material Modification to Rights of Security Holders The information set forth in

Regulation FD Disclosure ​ On June 16, 2025, the Company issued a press release announcing the Licensing Agreement and the Private Placement and made publicly available a corporate presentation that included information on SIM0505. A copy of the press release and the data presentation are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein. The exhibits furnished under

Unregistered Sales of Equity Securities ​ To the extent required by Form 8-K, the disclosures in

Entry into a Material Definitive Agreement ​ Licensing Agreement On June 13, 2025, NextCure, Inc. (“NextCure” or the “Company”) entered into a License Agreement (the “Licensing Agreement”) with Hainan Simcere Zaiming Pharmaceutical Co., Ltd. (“Zaiming”), a biopharmaceutical company based in China. Pursuant to the Licensing Agreement, the Company obtained (1) an exclusive, worldwide (excluding the Zaiming Territory, as identified below) license to develop, manufacture, and commercialize Zaimin…

Results of Operations and Financial Condition ​ On May 1, 2025, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. ​ The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth…

Results of Operations and Financial Condition ​ On March 6, 2025, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2024. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. ​ The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or o…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. ​ On January 31, 2025, NextCure, Inc. (the “Company”, “we”, “us”, or “our”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying us that the closing price of our common stock over the prior 30 consecutive business days had fallen below $1.00 per share, which is the minimum average closing price required to mainta…